Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Corbus Pharmaceuticals (0SZI) Share Price & Analysis

0 Followers

0SZI Stock Chart & Stats

$3.45$0.06(1.77%)
At close: 4:30 PM GMT
$2.5$5$7.5$10Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$3.25 - $3.53
52-Week Range
$2.91 - $14.57
Previous Close
$3.39
Volume
N/A
Average Volume (3M)
13.46K
Market Cap
$69.86M
Enterprise Value
$30.69M
Total Cash (Recent Filing)
$115.34M
Total Debt (Recent Filing)
$3.91M
Price to Earnings (P/E)
―
Beta
1.56
Next Earnings
Mar 15, 2027 (Est.)
EPS Estimate
-1.42
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Obesity Pipeline Differentiation

Positive CANYON-1 results provide clinical support for CRB-913 as a potentially differentiated oral, non-incretin obesity treatment. Durable weight loss, no observed plateau, and favorable tolerability could strengthen the candidate’s competitive positioning as development advances.

Phase 3 Oncology Progress

FDA clearance and initiation of a randomized Phase 3 oncology study mark meaningful advancement toward a potential registration pathway. The trial’s objective response and overall survival endpoints create defined value inflection points and support pipeline maturity.

Low Financial Leverage

Very low debt reduces fixed financial obligations and avoids adding substantial interest or refinancing pressure while Corbus funds clinical development. This provides more balance-sheet flexibility than a highly leveraged structure, despite the company’s operating losses.

Bears Say

Pre-revenue Operating Model

Corbus remains pre-revenue while losses are widening materially, so the business has not yet demonstrated commercial operating leverage. Continued development spending without product revenue leaves future financial performance highly dependent on clinical progress and eventual approvals.

Persistent Cash Burn

Large and worsening free-cash-flow outflows show that clinical development is consuming substantial cash and that reported losses are translating into real funding needs. Unless operating economics improve, Corbus will remain dependent on financing or available reserves.

Eroding Capital Base

The decline in equity indicates that sustained losses and cash burn are reducing the company’s capital base over time. This weakens financial resilience and can increase reliance on external funding, particularly if development costs remain elevated before commercialization.

Corbus Pharmaceuticals News

0SZI FAQ

What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest share price was $2.91 and its highest was $14.57 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $69.86M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s next earnings report is estimated for Mar 15, 2027 (not yet confirmed), which is in 120 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Nov 10, 2026. The company reported -$1.81 earnings per share for the quarter, missing the consensus estimate of -$1.273 by -$0.537.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.42.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 20,606,760 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.81 in its last earnings report, missing expectations of -$1.273. Following the earnings report the stock price went up 5.191%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Hedge funds hold Corbus Pharmaceuticals shares: the largest hedge-fund position in Corbus Pharmaceuticals is 988,880,170 shares, and hedge funds increased their holdings by 39.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology